Drug Trial Radar · NCT07764861
A Open-Label Phase in Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 15, 2026
Primary completion
Dec 31, 2026
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma. This study includes a safety run-in period and 2 cohorts (Cohorts 1 and 2).In the safety run-in period, subjects with measurable relapsed or refractory multiple myeloma who had previously received at least 1 line of systemic anti-myeloma therapy and had a history of dual drug exposure (at least one proteasome inhibitor and one immunomodulatory agent) were enrolled, mainly to evaluate the safety and tolerability of IBI3003 in combination with anti-CD38 monoclonal antibody and to determine the recommended phase 2 dose of IBI3003 in combination with anti-CD38 monoclonal antibody.Cohort 1 mainly enrolls newly diagnosed MM(Multiple myeloma)patients who are ineligible for or refusing ASCT(Autologous Stem Cell Transplantation), and Cohort 2 enrolls newly diagnosed MM patients who are eligible for and willing to undergo ASCT. The 24-week MRD negative rate of IBI3003 in combination with anti-CD38 monoclonal antibody in the participant population is mainly evaluated.
Conditions
- Multiple Myeloma
Interventions
DexamethasoneDrug
A potent synthetic glucocorticoid
IBI3003Biological
Recombinant humanized anti-GPRC5D/BCMA/CD3 trispecific antibody injection
LenalidomideDrug
An Oral Immunomodulator And Antineoplastic Drug
DaratumumabDrug
Anti-cancer monoclonal antibody targeting CD38
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRD( Minimal Residue Disease) negativity rate at 24 weeksTime frame: 24weeks
- AE(Adverse event)Time frame: 30Days
- TEAE(Treatment emergent adverse event)Time frame: 30Days
- SAE(Serious Adverse Event)Time frame: 30Days
- AESI( Adverse event of special interest)Time frame: 30Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.